Porter, Verna R., M.D., F.A.N.A.
  • Health Sciences Professor of Neurology, David Geffen School of Medicine at UCLA

  • Director of Clinical Programs, Mary S. Easton Center for Alzheimer's Disease Research at UCLA

Porter, Verna R., M.D., F.A.N.A.


Mary S. Easton Center for Alzheimer's Disease Research at UCLA
710 Westwood Plaza, Room C-224
Los Angeles, CA 90095-1769
Tel: (310) 794-3665
Appointments: (310) 794-6039 {Memory Evaluation}
Fax: (310) 794-3148
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Neurology, Alzheimer's Disease, Memory Disorders, Dementia, Neuroimmunology and Neurogerontology.



  • B.S., Department of Microbiology and Immunology, UCLA, 1986-1990.
  • M.D., David Geffen School of Medicine at UCLA, 1990-1994.
  • Internship, Internal Medicine, David Geffen School of Medicine at UCLA, 1994-1995.
  • Residency, Neurology, David Geffen School of Medicine at UCLA, 1995-1998.
  • Combined Fellowship Program, Geriatrics and Behavioral Neurology and Neuropsychiatry, Department of Neurology and Division of Geriatrics, David Geffen School of Medicine at UCLA, 1998-2000.


Honors and Awards

1986 UCLA Faculty Women's Scholarship.
1986 UCLA Alumni Scholar (Regional and Area Winner).
1986 UCLA Regents' Scholar.
1990 Honors in the Major: Microbiology/Immunology.
1990 College Honors upon graduation from UCLA.
1989-1990 Secretary (UCLA Chapter) and Member, Mortar Board National Honor Society.
1988-1990 Vice President (UCLA Chapter) and Member, Golden Key National Honor Society.
1990 Magna Cum Laude, upon graduation from UCLA.
1990 Elected to Phi Beta Kappa National Honor Society.
1991 John S. Hartford Foundation/AFAR Research Award.
1994 Receipt of Richard D. Walter Award for the outstanding senior medical student during a neurology clerkship.
1994 UCLA School of Medicine Dean's Scholar for Research.
1997, 1998 Receipt of Jean Louis-Riehl Research Award to a Neurology Resident for outstanding research.
1998-1999 Awarded Bureau of Health Professions Fellowship Training Stipend.
1999-2000 Awarded UCLA Claude Pepper Center (OAIC) Career Development Award.
12/14/2005 Young Physician Leaders Dinner: Chosen by the UCLA Medical Staff Office and the California Medical Association as a "Leader Among Young Physicians", Regional Recognition Dinner, Los Angeles, CA.
2004-2014 Selected for inclusion in Guide to America's Top Physicians by the Consumers' Research Council of America (Washington, D.C. based research organization that provides consumers' information guides for professional services throughout America).
2009-2014 editions Selected for inclusion in Marquis Who's Who in America.
2010-2014 editions Selected to be listed in the 2010 Southern California Super Doctors, Selected for inclusion in the 2010 Los Angeles Magazine, Top Doctors.
2010-2014 editions Selected to be listed in the Southern California Super Doctors, Los Angeles Magazine (features top five percent of doctors in Los Angeles and Orange counties) superdoctors.com.
2011-2014 editions Selected to be listed in the Top Women Southern California Super Doctors (top women physicians from the January Southern California Super Doctors list as published).
2011-2014 editions Selected for Cambridge Who's Who: Registry of Executive and Professional Women.
2011-2014 editions Selected for inclusion in Marquis Who's Who in Medicine and Healthcare.
2012-2014 editions Selected for inclusion in Marquis Who's Who in the World.
2011-2014 Selected for National Association of Professional Women.
2011-2014 Selected as a Top Neurologist in Santa Monica, CA by the International Assoc. of Healthcare Professionals (IAHCP). The Leading Physicians of the World is a subsidiary of the International Association of HealthCare Professionals which is made up of over 100 different medical societies.
03/2012-present Fellow, American Neurological Association.


Board Certifications

2000-present Diplomate, American Board of Psychiatry and Neurology.
2009-present Maintenance of Certification (MOC) Exam for Diplomate, American Board of Psychiatry and Neurology.
2012-present Subspecialty Certification: United Council of Neurologic Subspecialties (UCNS) in Behavioral Neurology and Neuropsychiatry.



  • Effros RB, Boucher N, Porter VR, Zhu X, Spaulding, C, Walford RL, Kronenberg M, Cohen D, Schachter F. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994;29(6):601-609.
  • MacKenzie-Graham AJ, Pribyl TM, Kim S, Porter VR, Campagnoni AT, Voskuhl RR. Myelin protein expression is increased in lymph nodes of mice with relapsing experimental autoimmune encephalomyelitis. J Immunol 1997;159(9):4602-4610.
  • Porter VR, Greendale G, Schocken M, Zhu X, Effros RB. Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol 2001;36(2):311-326.
  • Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, Cummings JL, Effros RB. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003;24(1):77-84.
  • Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, Cummings JL. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J Neuropsychiatry Clin Neurosci 2003;15(2):180-186.
  • Mega MS, Dinov ID, Porter VR, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Felix J, Amezcua H, Cummings JL. Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy: An FDG-PET Study. Arch Neurol 2005;62(5):721-728.
  • Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter VR, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood of male patients with mild Alzheimer’s disease and healthy elderly men. Arch Neurol 2006;63(2):177-185.
  • Porter VR. The International Management of Stroke (IMS) II Study. Stroke 2007;38:2127-2135.< br/>
  • Rahiman A, Saver JL, Porter VR, Buxton W, McNair N, Razinia T, Ovbiagele B. In-hospital initiation of secondary prevention is associated with improved vascular outcomes at 3 months. J Stroke Cerebrovasc Dis 2008;17(1):5-8.
  • Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, Del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators (Porter VR as an investigator for CLEAR Trial). The Combined Approach to Lysis Using Eptifibatide and rt-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial. Stroke 2008;39(12):3268-3276. PMCID: PMC2588546
  • Avagyan H, Goldenson B, Masoumi A, Porter VR, Wiedau-Pazos M, Sayre J, Ong R, Tse E, Koo P, Bae S, Mahanian M, Micic M, Liu P, Rosenthal M, Fiala M. Immune blood biomarkers of Alzheimer disease patients. Journal of Neuroimmunology 2009;210(1-2):67-72.
  • Fiala M, Mahanian M, Rosenthal M, Mizwicki MT, Tse E, Cho T, Sayre J, Weitzman R, Porter VR. MGAT3 mRNA: A Biomarker for Prognosis and Therapy of Alzheimer’s Disease by Vitamin D and Curcuminoids. Journal of Alzheimer's Disease 2011;25(1):135–144. PMID: 21368380
  • Prado E, Paholpak P, Ngo M, Porter VR, Apostolova L, Marrocos R, Ringman J. Agitation and psychosis associated with dementia with Lewy bodies exacerbated by Modafanil use. Am J Alzheimers Dis Other Demen 2012;27(7):468-473. PMCID: PMC4005870
  • Saver JL, et al. (Porter VR as investigator for SWIFT trial). Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380(9849):1241-1249. doi:10.1016/S0140-6736(12)61384-1
  • Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; the TREVO 2 Trialists (Porter VR as investigator for TREVO 2). Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380(9849):1231-1240. PMCID: PMC4176618
  • Pancioli AM, Adeoye O, Schmit PA, Khoury J, Levine SR, Tomsick TA, Sucharew H, Brooks CE, Crocco TJ, Gutmann L, Hemmen TM, Kasner SE, Kleindorfer D, Knight WA, Martini S, McKinney JS, Meurer WJ, Meyer BC, Schneider A, Scott PA, Starkman S, Warach S, Broderick JP; CLEAR-ER Investigators (Porter VR as investigator for CLEAR-ER). Combined Approach to Lysis Utilizing Eptifibatide and recombinant tissue plasminogen activator in Acute Ischemic Stroke-Enhanced Regimen Stroke Trial. Stroke 2013;44(9):2381-2387. doi: 10.1161/STROKEAHA.113.001059. PMCID: PMC3970761
  • Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators (Porter VR as investigator for CLEAR-ER). Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368(10):893-903. doi: 10.1056/NEJMoa1214300.
  • Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL; MR RESCUE Investigators (Porter VR as investigator for MR RESCUE). A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368(10):914-923. doi: 10.1056/NEJMoa1212793.
  • Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter VR, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM. Oral Curcumin for Alzheimer's Disease: Tolerability and Efficacy in a 24-Week Randomized, Double Blind, Placebo-Controlled Study. Alzheimer's Research & Therapy 2012;4(5):43. PMCID: PMC3580400
  • Ting SKS, Benzinger T, Kepe V, Fagan A, Coppola G, Porter VR, Hecimovic S, Chakravertyh S, Alvarez-Retuerto AI, Goate A, Ringman JM. A novel PSEN1 Mutation (I238M) associated with early-onset Alzheimer's disease in an African-American woman. Journal of Alzheimer's Disease 2014;40(2):271-275. doi: 10.3233/JAD-131844. PMCID: PMC3972314

Book Chapters

  • Porter VR and Weiner DB. Historical Perspectives on Cadmium-Induced Nephrotoxicity. In: Bach PH and Lock EA, Eds., Nephrotoxicity: Extrapolation from In vitro to In vivo, and Animals to Man, Plenum Press, London, 1989, pp.51-58.
  • Porter VR and Buxton WB. The Clinical Approach to the Patient with Dementia. In: Collins RC and Kidwell SC, Eds. UCLA Medical Student's Handbook. UCLA Academic Press, Los Angeles, 1999. (copyright: UCLA Department of Neurology).
  • Porter VR and Cummings JL. Dementia in Women. In: Pregler J and DeCherney A, Eds. Principles of Women's Health. B.C. Decker Inc., London, 2002, pp.697-703.


  • Fiala M and Porter V. Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy. Biomarkers Med 2011;5(5):645-647.